Posts Tagged CMO

CMOs Must Embrace Flexible Manufacturing

by

The need for flexibility in manufacturing arrangements and technologies has never been greater. New products are more technically challenging, produced in smaller volumes, and subject to great market uncertainty stemming from competing therapies and reimbursement risk. Contract development and manufacturing organizations (CDMOs) need to respond in both technical capabilities and business model flexibility to address […]

Learn more

Contract Manufacturing Through the Years

by

How has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hold? The 40 years during which Pharmaceutical Technology has served the bio/pharmaceutical industry have been years of momentous growth and change in the way drugs are discovered, developed, manufactured, and sold. Contract development and manufacturing organizations (CDMOs) have long […]

Learn more

Growing Mexico Is Home to Solid CMO Population

by

Proximity to the US, a strong regulatory scheme, affordability and decades-long relationships forged with the help of the North American Free Trade Agreement (NAFTA) are among the factors that may make Mexico an attractive location for contract manufacturing services, particularly for products sold in the US or Latin American markets. The country is also fairly […]

Learn more

CMOs and CROs Have Different Trajectories

by

CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate. A growing number of observers, including the Wall Street analysts that follow the publicly-traded contract research organizations (CROs) and contract manufacturing organizations (CMOs), have made statements recently suggesting that the CMO industry is following the […]

Learn more

2016 Results Summary: A Rising Tide Lifts All Contract Service Boats

by

The Contract Development and Manufacturing Organization (CDMO) sector enjoyed a strong 2016, with all components reporting robust, albeit uneven, growth. Early-stage companies posted especially impressive results, bolstered by generous external funding, and the API sector continued its recent recovery, especially in the small molecule space (see Figure 1, below). The impressive top line results do, […]

Learn more

NDA Outsourcing Up, Despite NME Decline

by

In 2016, outsourced dose form manufacturing of NDA approvals reached 60%, some 10% higher than the five-year average. This and other insights into CMO performance were revealed in PharmSource’s recently published CMO Scorecard. In what proved to be a mediocre year for drug approvals, the increase in outsourcing levels was restricted to the manufacture of […]

Learn more

Time to Hit the Road!

by

The pharma trade show season is officially in full swing! Whether your organization is a CRO, CMO, CDMO or any other service provider to the pharma/biotech/device and diagnostics industry, chances are you’ve either recently attended, or will be attending, an industry event over the next few months. If this is the case, make sure you’re […]

Learn more

Will Pharma Manufacturing Move Back to the US?

by

Moving global manufacturing operations may be more complicated than it appears. The bio/pharmaceutical industry is still buzzing about President Trump’s meeting with pharmaceutical executives on Jan. 31, 20171. While promising the industry lower taxes and less regulation, the President emphasized that those benefits will come only if the industry lowers drug prices and moves more […]

Learn more

AGC Acquires CMC Biologics

by

AGC Asahi Glass has agreed to acquire biomanufacturer CMC Biologics in a deal valued at ¥60 billion ($500 million). PharmSource estimates that the price represents a multiple of about 3.3x revenues and more than 10x EBITDA. The selling shareholders are three private equity firms: Monitor Clipper Partners; European Equity Partners; and Innoven Partenaires. Closing is […]

Learn more

Catalent to Acquire Accucaps

by

Catalent has agreed to acquire softgel manufacturer Accucaps Industries Ltd. Financial details of the transaction were not disclosed, but analysts that follow Catalent put the price at $75 million, representing a multiple of 10x EBITDA. The deal is subject to Canadian regulatory approval. Accucaps is owned by Canadian generic pharmaceutical company Apotex, a detail not […]

Learn more